Piramal Pharma Limited Response to Exchange Surveillance Query
Summary of Clarification
Piramal Pharma Limited has issued a formal response to a clarification sought by the stock exchanges regarding a significant movement in its share price.
Date and Nature of Exchange Communication
The company received a communication from the Surveillance Departments of both BSE Limited and the National Stock Exchange of India Limited on 23rd June, 2026. The query sought clarification on a news article appearing on NDTV Profit on the same date, captioned "Piramal Pharma Share Price Spikes Over 10% — What Is Driving The Rally?"
Company’s Clarification on Trading and News
The company's clarification, signed by Company Secretary & Compliance Officer Maneesh Sharma, addresses the query with the following key points:
- The referenced news article is confirmed to be located at: https://www.ndtvprofit.com/markets/piramal-pharma-shares-surge-over-10-percent-following-multiple-global-regulatory-approvals-11674176.
- The company states that the article "does not contain any material information or event requiring disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015."
- The company is not aware of any specific reason or information that caused the observed price movement and attributes it to "market dynamics."
Regulatory Compliance Reference
The clarification explicitly references compliance with SEBI Listing Regulations, specifically Regulation 30, which governs the disclosure of events and information. The company affirms that "all information furnished by the Company is already in the public domain" and that "there is no material event or information requiring disclosure under Regulation 30... that remains undisclosed."
Details of Financial Results Clarification
This specific document does not discuss or provide any clarification on financial results. The entire communication is focused on addressing the price volume movement and the news article.